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Resistanceofrhabdomyosarcomatocurrenttherapiesremainsoneofthekeyissuesinpediatriconcology.Sincethesuccessofmost
cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate
programmed cell death (apoptosis), defects in apoptosis programs in cancer cells may result in resistance. Evasion of apoptosis
in rhabdomyosarcoma may be caused by defects in the expression or function of critical mediators of apoptosis or in aberrant
expression of antiapoptotic proteins. Therefore, the identiﬁcation of the molecular mechanisms that confer primary or acquired
resistance to apoptosis in rhabdomyosarcoma presents a critical step for the rational development of molecular targeted drugs.
This approach will likely open novel perspectives for the treatment of rhabdomyosarcoma.
1.Introduction
The appropriate balance between cell growth and cell death
is a critical factor to maintain tissue homeostasis in multicel-
lular organisms [1]. Thus, too little cell death as well as too
much proliferation can contribute to tumor formation and
progression [2, 3]. Apoptosis is the form of programmed cell
death that is currently best characterized [4]. Further, defects
in apoptosis programs may confer resistance to cytotoxic
therapies, since the success of many anticancer therapies that
are currently used in the treatment of cancer such as chemo-,
radio-, or immunotherapy critically depends on intact cell
death pathways [5]. This implies that a better understanding
of the molecular mechanisms that control cell death path-
ways in cancer, for example, in rhabdomyosarcoma (RMS),
will likely open novel opportunities for the development of
innovative treatment strategies. In this paper, the deregula-
tion of cell death programs in RMS will be discussed as well
as possibilities to target cell death pathways for therapeutic
purposes.
2. Rhabdomyosarcoma
RMS constitutes the most frequent form of soft tissue
sarcoma in childhood and comprises two major histological
subtypes that are characterized by typical genetic aberra-
tions, that is, embryonal rhabdomyosarcoma (ERMS) and
alveolar rhabdomyosarcoma (ARMS) [6]. Loss of heterozy-
gosity (LOH) at chromosome 11p15.5 is often found in
ERMS. ARMS frequently harbors reciprocal chromosomal
translocations between chromosome 2 or chromosome 1
and chromosome 13, that is, t(2; 13) and t(1; 13) resulting
in chimeric fusion genes composed of the DNA-binding
domain of PAX3 or PAX7 from chromosome 2 or 1 and
the transactivation domain of FOXO1A from chromosome
13 [7]. Furthermore, the p53 pathways are frequently altered
in RMS with p53 mutations in about half of the cases [7].
Alternatively, MDM2 ampliﬁcation or overexpression may
cause inactivation of the p53 pathway in RMS [7]. Although
the prognosis is usually more favorable in ERMS compared
toARMS,theoverallsurvivalforadvancedmetastaticdisease
still remains poor despite aggressive treatment regimens [8,
9]. This underscores that innovative treatment strategies are
required to improve patients’ survival.
3.Apoptosis Pathway
Two key apoptosis signaling pathways can be distinguished,
that is, the extrinsic (death receptor) pathway and the intrin-
sic (mitochondrial) pathway. Activation of either pathway2 Sarcoma
typically results in the activation of caspases, a group of
cysteine proteases that constitute the central execution
machinery of apoptosis [4]. Activation of the extrinsic path-
way following ligation of death receptors leads to the activa-
tion of caspase-8 [10]. Death receptors are members of the
tumor necrosis factor (TNF) receptor gene superfamily and
comprise as prominent examples TNF receptor 1 (TNFRI),
CD95 (APO-1/Fas), and TNF-related apoptosis-inducing
ligand (TRAIL) receptors [10]. Caspase-8 activation can
resultindirectactivationofcaspase-3.Alternatively,caspase-
8 can cleave and thereby activate Bid into tBid, which
translocates to mitochondria to initiate the mitochondrial
pathway of apoptosis. The mitochondrial pathway involves
the release of cytochrome c, apoptosis-inducing factor (AIF),
or Smac/DIABLO from the mitochondrial intermembrane
space into the cytosol [11]. Cytochrome c then drives the
activationofcaspase-3viatheapoptosome,whileSmacfunc-
tions in a proapoptotic manner by antagonizing “Inhibitor
of Apoptosis” (IAP) proteins [11]. IAP proteins are a family
of antiapoptotic proteins with eight human analogues, in-
cluding XIAP, cIAP1, and cIAP2 [12]. IAP proteins block
apoptosis signaling at a central node by interfering with
the activation of eﬀector caspases [12]. Another level of
regulation is provided by the Bcl-2 family of proteins. They
comprise both antiapoptotic proteins (i.e., Bcl-2, Bcl-XL,
Mcl-1) as well as proapoptotic molecules (i.e., Bax, Bak, and
BH3 domain only proteins) [13].
4. Modulation of Apoptosis Signaling Pathways
for the Treatment of Sarcoma
Based on the considerable advances that were made during
the last two decades in the understanding of the regulation
of apoptosis pathways in human cancers, a number of strat-
egies were developed to target apoptosis signaling pathways
for therapeutic purposes. These approaches aim at shifting
the balance between pro- and antiapoptotic signals towards
the induction of apoptosis either by directly engaging
proapoptotic molecules or pathways or indirectly by antago-
nizing antiapoptotic breaks. Prominent examples include the
engagement of death receptors on the cell surface by ligands
or antibodies, the inhibition of antiapoptotic proteins of the
Bcl-2 families, and the neutralization of IAP proteins. These
strategiesandtheir implications forRMSarediscussed inthe
following paragraphs.
5.TargetingDeathReceptorsviaTRAIL inRMS
RMS cell lines were found to be relatively responsive
towards the death receptor ligand TRAIL compared to their
resistance to CD95-induced cell death [14]. Nevertheless,
cases of resistance to TRAIL-induced apoptosis have also
been described for RMS and have been attributed to
diﬀerent mechanisms. For example, high expression levels
of antiapoptotic proteins such as cFLIP or Bcl-2 have been
linked to TRAIL resistance in RMS [14, 15]. In addition, the
serine/threonine kinases casein kinase I or casein kinase II
have been reported to block TRAIL-induced apoptosis by
interfering with the recruitment of FADD and procaspase-8
to the death-inducing signaling complex (DISC) [16, 17].
Moreover, epigenetic silencing of caspase-8 has been
identiﬁed as a resistance mechanism in response to death
receptor stimulation in a small proportion of RMS cell lines
and primary tumor specimens [14, 18, 19]. Inactivation of
caspase-8byhypermethylationofregulatorysequencesofthe
caspase-8 gene occurs in several human cancers in addition
to RMS, for example, in neuroblastoma, medulloblastoma,
Ewing tumors, and small-cell lung cancer both in cell lines as
wellasinprimarytumorsamples[20].Ofnote,upregulation
of caspase-8 expression restored the sensitivity to death-
receptor- or anticancer drug-induced apoptosis [18, 21–
25]. RMS cell lines were found to primarily express TRAIL
receptor 2 (TRAIL-R2), one of the two agonistic TRAIL
receptors [26]. Accordingly, a TRAIL-R2-targeted therapeu-
tic antibody proved to be eﬀective in vitro against the major-
ity of RMS cell lines and exerted potent antitumor activity
against established RMS xenografts in vivo [26]. Also, a
strong correlation between the sensitivity to a TRAIL-R2 ag-
onistic antibody and caspase-8 expression was reported in
line with the notion that caspase-8 presents a critical reg-
ulator of the death receptor pathway of apoptosis, which is
epigenetically silenced in a subset of RMS [26].
To enhance the antitumor activity of TRAIL, combina-
tion regimens were developed together with DNA-damaging
agents such as chemotherapeutic drugs or γ-irradiation. For
example, doxorubicin was reported to potentiate TRAIL-
induced cytotoxicity in RMS cell lines [27, 28]. Furthermore,
the proteasome inhibitor MG132 enhanced TRAIL-induced
apoptosis via upregulation of TRAIL-R2 expression [29].
In a melphalan-resistant RMS cell line, TRAIL increased
melphalan-induced cytotoxicity via a caspase-2- and -3-
dependent mechanism [30].
I na na t t e m p tt od e l i v e rT R A I Lt ot h et u m o rs i t et ot r i g -
ger apoptosis, bone-marrow-derived mesenchymal stroma
cells (BM-MSCs) were eﬃciently transduced to express a
TRAIL vector [31]. Interestingly, TRAIL-expressing MSCs
were reported to eﬀectively kill RMS cells in vitro [31]. Along
the same lines, TRAIL expression on cytokine-induced killer
(CIK) cells has been linked to CIK-mediated antitumor
activity [32]. These studies indicate that cell-mediated
delivery of TRAIL to RMS might present a useful strategy to
engage the death receptor pathway of apoptosis in RMS.
6. Bcl-2 Family of Proteins
The Bcl-2 family of proteins consists of a number of both
a n t i a p o p t o t i ca sw e l la sp r o a p o p t o t i cp r o t e i n s[ 13]. It is
important to keep in mind that the sensitivity to apoptosis
is primarily regulated by the ratio of antiapoptotic versus
proapoptotic Bcl-2 proteins rather than the expression levels
of one particular Bcl-2 family protein.
Alterations of Bcl-2 family proteins frequently occur
in human cancers. Genetic aberrations may contribute to
aberrantly high expression of antiapoptotic Bcl-2 proteins.
For example, chromosomal translocation or oncogenic acti-
vation of survival pathways may cause increased expression
levels of Bcl-2 family proteins. In RMS, both PAX3 andSarcoma 3
PAX3/FKHR transcription factors were reported to tran-
scriptionally stimulate Bcl-XL mRNA expression [33]p r o -
viding genetic links between RMS tumorigenesis and activa-
tion of antiapoptotic programs. Furthermore, several anti-
apoptotic proteins, including Bcl-2, Bcl-XL, and Survivin,
belongtothetargetgenesofsignaltransducersandactivators
of transcription 3 (STAT3), which has been shown to be
constitutively activated in RMS cell lines [34]. Accordingly,
treatment with a small molecule STAT3 inhibitor, that is,
XZH-5, caused suppression of Bcl-2, Bcl-XL, and Survivin
and resulted in increased apoptosis in RMS cells [35].
In addition, there is evidence that increased activity of
the hedgehog pathway may trigger upregulation of Bcl-2
proteins. Enhanced hedgehog pathway signaling is typically
associated with elevated levels and activity of Gli proteins,
transcription factors that mediate the transcriptional activa-
tionofhedgehogtargetgenes[36].Ofnote,Gliproteinswere
reported to stimulate transcription from the Bcl-2 promoter
[37]. More speciﬁcally, Gli-1 was shown to transactivate
the Bcl-2 promoter, while Gli-3 inhibits transactivation
by Gli-1 [37]. The notion that Bcl-2 is controlled at the
transcriptional level by the hedgehog pathway is further
supported by data obtained in a hedgehog-driven murine
model of RMS. Accordingly, RMSs that develop in Ptch1
deﬁcient mice were reported to display increased Bcl-2 levels
[38].
An immunohistochemical study revealed that both Bcl-2
and Bax were expressed in RMS tumor samples [39]. Of
note, patients whose tumors exhibited Bax expression were
reported to experience a signiﬁcantly longer overall survival
[39]. Also, Bax expression was found to be associated with
increased chemosensitivity of RMS cells to doxorubicin
and actinomycin D [40]. In addition, Bax activation was
described to be required for sphingosine-induced apoptosis
in RMS cell lines [41]. Besides Bcl-2 and Bax, overexpression
of Mcl-1, another antiapoptotic protein of the Bcl-2 family,
was reported in RMS [42]. Recently, the glycolytic inhibitor
2-deoxyglucose (2-DG) was reported to trigger apoptosis in
alveolar, but not embryonal, RMS cell lines [43]. Induction
of cell death was accompanied by downregulation of Mcl-1
as well as upregulation of Noxa, a proapoptotic Bcl-2 family
protein [43].
Since high expression levels of antiapoptotic Bcl-2 pro-
teins can confer resistance to current treatment approaches
by blocking the activation of the mitochondrial pathway,
several strategies have been developed in recent years to
antagonize the cytoprotective functions of antiapoptotic
Bcl-2 proteins. A prominent example is small molecule
Bcl-2 inhibitors, which interfere with the protein-protein
interaction site between antiapoptotic Bcl-2 proteins and
the multidomain proteins Bax or Bak [44]. Despite overex-
pression of antiapoptotic Bcl-2 proteins in RMS, ABT-263,
a second-generation compound that inhibits Bcl-2, Bcl-XL,
and Bcl-w, demonstrated limited in vivo activity against the
PPTP’s solid tumor panels including RMS when tested as
single agent [45]. This indicates that rational combination
treatments may be required to exploit Bcl-2 inhibitors in
RMS.
7.IAP Proteins
Sensitivity or resistance to apoptosis may also be controlled
by IAP proteins, for example, XIAP, cIAP1, and cIAP2
[12]. Among the IAP proteins, XIAP exhibits the strongest
antiapoptotic properties and blocks apoptosis by binding to
andinhibitingactivecaspase-3and-7andbyinterferingwith
the activation of caspase-9 [12]. IAP proteins are considered
as promising targets for therapeutic intervention in human
cancers. However, little is yet known about the role and
relevance of these proteins in RMS. cIAP2 was shown to
be upregulated following exposure to hypoxia in RMS cells
and may contribute to apoptosis resistance under these
conditions [46]. Notably, downregulation of XIAP by the
antisenseoligonucleotideAEG35156wasrecentlyreportedto
induce apoptosis in RMS cells [47]. These ﬁndings point to
a potential impact of strategies that antagonize IAP proteins
in RMS and suggest that additional studies are required to
evaluate IAP proteins as therapeutic targets in RMS.
8. Conclusions
Programmed cell death is a key regulator of tissue home-
ostasis and plays a central role in tumorigenesis. In addi-
tion, intactness of apoptosis pathways constitutes a critical
determinant of the sensitivity versus resistance of RMS to
most current treatment strategies. The discoveries over the
lastyearsontheregulationofapoptosissignalingpathwaysin
RMS resulted in the identiﬁcation of new molecular targets,
which can be exploited for the development of innovative
experimental therapies, for example, TRAIL receptor ago-
nists, small molecule inhibitors of antiapoptotic Bcl-2 pro-
teins, or strategies targeting IAP proteins. One key challenge
in the future will be to develop biomarkers in order to
identify the group(s) of patients that will proﬁt the most
from these molecular targeted therapies. Also, it will likely be
criticaltodeveloprationalcombinationtherapiesusingthese
signal transduction modulators together with conventional
cancer therapies such as chemo- or radiotherapy in order
to exploit synergistic interactions. Hopefully, this strategy to
engage cell death signaling pathways in RMS cells will open
new avenues for the treatment of RMS patients.
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